INT19541

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 1981
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 22
Total Number 27
Disease Relevance 15.42
Pain Relevance 5.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Ptgir) signal transducer activity (Ptgir)
Anatomy Link Frequency
endothelial cells 5
liver 4
DRG 3
smooth muscle 2
platelet 2
Ptgir (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 59 100.00 Very High Very High Very High
ischemia 2 99.58 Very High Very High Very High
dorsal root ganglion 24 99.56 Very High Very High Very High
Inflammation 12 99.16 Very High Very High Very High
antagonist 112 97.56 Very High Very High Very High
Serotonin 30 97.36 Very High Very High Very High
Migraine 6 94.72 High High
Analgesic 5 94.24 High High
Dopamine 1 92.52 High High
adenocard 1 92.32 High High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 120 99.96 Very High Very High Very High
Arteriosclerosis Obliterans 2 99.84 Very High Very High Very High
Cv Unclassified Under Development 2 99.58 Very High Very High Very High
Ganglion Cysts 27 99.56 Very High Very High Very High
Colon Cancer 28 99.50 Very High Very High Very High
Stress 5 99.40 Very High Very High Very High
INFLAMMATION 21 99.16 Very High Very High Very High
Pulmonary Hypertension 738 99.10 Very High Very High Very High
Hypertension 25 98.10 Very High Very High Very High
Cystitis 3 96.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the present study, PCR experiments revealed that one of prostanoid receptor, prostacyclin receptor (IP receptor) was expressed in L6 and S1 rat DRG neurons and that the expression of IP receptor was not changed in DRG neurons obtained from the cyclophosphamide (CYP)-induced cystitis rat.
Gene_expression (expression) of IP receptor in DRG associated with dorsal root ganglion and cystitis
1) Confidence 0.65 Published 2005 Journal Neurosci. Lett. Section Abstract Doc Link 16039053 Disease Relevance 0.86 Pain Relevance 0.66
Prostacyclin (PGI2), a major metabolite of arachidonic acid, is widely distributed throughout the cardiovascular system and may influence vascular smooth muscle tone.
Gene_expression (distributed) of Prostacyclin in smooth muscle
2) Confidence 0.53 Published 1982 Journal Arch Int Pharmacodyn Ther Section Abstract Doc Link 6762168 Disease Relevance 0 Pain Relevance 0
Prostacyclin produced minimal vasodilation of arteries or veins.
Gene_expression (produced) of Prostacyclin in veins associated with increased venous pressure under development
3) Confidence 0.52 Published 1989 Journal Vet Surg Section Abstract Doc Link 2773284 Disease Relevance 0.18 Pain Relevance 0.10
In the present study, PCR experiments revealed that one of prostanoid receptor, prostacyclin receptor (IP receptor) was expressed in L6 and S1 rat DRG neurons and that the expression of IP receptor was not changed in DRG neurons obtained from the cyclophosphamide (CYP)-induced cystitis rat.
Gene_expression (expressed) of prostacyclin receptor in DRG associated with dorsal root ganglion and cystitis
4) Confidence 0.50 Published 2005 Journal Neurosci. Lett. Section Abstract Doc Link 16039053 Disease Relevance 0.85 Pain Relevance 0.61
In the present study, PCR experiments revealed that one of prostanoid receptor, prostacyclin receptor (IP receptor) was expressed in L6 and S1 rat DRG neurons and that the expression of IP receptor was not changed in DRG neurons obtained from the cyclophosphamide (CYP)-induced cystitis rat.
Gene_expression (expressed) of IP receptor in DRG associated with dorsal root ganglion and cystitis
5) Confidence 0.50 Published 2005 Journal Neurosci. Lett. Section Abstract Doc Link 16039053 Disease Relevance 0.84 Pain Relevance 0.61
Lack of effect of ischemia and dipyridamole on prostacyclin production in arteriosclerosis obliterans.
Gene_expression (production) of prostacyclin associated with arteriosclerosis obliterans and ischemia
6) Confidence 0.48 Published 1981 Journal Prostaglandins Section Title Doc Link 7041195 Disease Relevance 0.46 Pain Relevance 0.17
Prostacyclin (PGI2) is a potent prostanoid producing various symptoms of inflammation, including an increased sensitivity to noxious stimulation.
Gene_expression (producing) of Prostacyclin associated with inflammation
7) Confidence 0.40 Published 1994 Journal Brain Res. Section Abstract Doc Link 7529126 Disease Relevance 0.10 Pain Relevance 0.29
Phospholipase inhibition and prostacyclin generation by gastric muscularis and mucosa layers.
Gene_expression (generation) of prostacyclin
8) Confidence 0.26 Published 1986 Journal Agents Actions Section Title Doc Link 3532720 Disease Relevance 0.07 Pain Relevance 0.11
It remains to be investigated whether the partial inhibition of the synthesis of PGI2, a major hyperalgesiccyclo-oxygenase product of arachidonic acid metabolism, at lower concentrations of the active metamizol metabolites contributes to the analgesic effect of metamizol.
Gene_expression (synthesis) of PGI2 associated with analgesic
9) Confidence 0.07 Published 1986 Journal Agents Actions Suppl. Section Abstract Doc Link 3092600 Disease Relevance 0.44 Pain Relevance 0.54
In patients with pulmonary hypertension, pulmonary endothelial cells have decreased expression of prostacyclin synthase89 and urinalysis demonstrates a decrease in stable prostacyclin metabolites.26
Gene_expression (expression) of prostacyclin in endothelial cells associated with pulmonary hypertension
10) Confidence 0.07 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.65 Pain Relevance 0.13
In patients with pulmonary hypertension, pulmonary endothelial cells have decreased expression of prostacyclin synthase89 and urinalysis demonstrates a decrease in stable prostacyclin metabolites.26
Gene_expression (synthase89) of prostacyclin in endothelial cells associated with pulmonary hypertension
11) Confidence 0.06 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.64 Pain Relevance 0.13
Ambrisentan, another selective ERA antagonist has recently been shown to improve exercise capacity in patients with PAH compared to placebo, and is well-tolerated.88

Prostacyclin agonists

Gene_expression (agonists) of Prostacyclin associated with pulmonary hypertension, antagonist and agonist
12) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.71 Pain Relevance 0.14
In patients with pulmonary hypertension, pulmonary endothelial cells have decreased expression of prostacyclin synthase89 and urinalysis demonstrates a decrease in stable prostacyclin metabolites.26
Gene_expression (metabolites.26) of prostacyclin in endothelial cells associated with pulmonary hypertension
13) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.63 Pain Relevance 0.12
Patients with PAH have increased levels of circulating endothelin-1.22,23 As well as causing vasoconstriction, endothelin-1 leads to smooth muscle and fibroblast proliferation via endothelin A (ETA), and/or endothelin B (ETB) receptors.24 Serotonin levels are also raised in PAH, which stimulates mitogenesis of vascular cells, and increased expression of the serotonin transporter is found in hypertensive arteries.25 Patients with severe PAH have a relative deficiency of vasodilator pathways; they produce less endogenous prostacyclin, have reduced nitrogen oxide synthase (NOS) expression, and reduced vasoactive intestinal peptide (VIP) in the lungs.26,27

Prevention of pediatric pulmonary hypertension

Gene_expression (produce) of prostacyclin in smooth muscle associated with pulmonary hypertension, hypertension, increased venous pressure under development and serotonin
14) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.98 Pain Relevance 0.13
Prostacyclin (PGI2) is a bioactive substance produced by vascular endothelial cells, which exerts powerful vasodilative and anti-platelet actions.
Gene_expression (produced) of Prostacyclin in platelet
15) Confidence 0.04 Published 1996 Journal J Cardiol Section Abstract Doc Link 8642506 Disease Relevance 0.29 Pain Relevance 0
Prostacyclin (PGI2) is a naturally occurring vasodilator and inhibitor of platelet aggregation that produces vasodilatation of the systemic, pulmonary and coronary vascular beds in animal models.
Gene_expression (produces) of Prostacyclin in platelet associated with increased venous pressure under development
16) Confidence 0.03 Published 1983 Journal Am. J. Cardiol. Section Abstract Doc Link 6351580 Disease Relevance 0.57 Pain Relevance 0.15
Consecutive therapy included the administration of norepinephrine, high frequency oscillatory ventilation (HFOV), Prostacyclin (PGI2) and extracorporeal membrane oxygenator (ECMO) therapy with entry criteria for each stage of treatment.
Gene_expression (administration) of Prostacyclin
17) Confidence 0.03 Published 1997 Journal Klin Padiatr Section Abstract Doc Link 9342718 Disease Relevance 0.34 Pain Relevance 0.14
RMICs do not express the prostacyclin receptor, but they do express the prostacyclin responsive nuclear transcription factor peroxisome proliferator-activated receptor delta (PPARdelta).
Neg (not) Gene_expression (express) of prostacyclin receptor
18) Confidence 0.02 Published 2002 Journal J. Biol. Chem. Section Abstract Doc Link 11927585 Disease Relevance 0.57 Pain Relevance 0.46
Patients with PAH have increased levels of circulating endothelin-1.22,23 As well as causing vasoconstriction, endothelin-1 leads to smooth muscle and fibroblast proliferation via endothelin A (ETA), and/or endothelin B (ETB) receptors.24 Serotonin levels are also raised in PAH, which stimulates mitogenesis of vascular cells, and increased expression of the serotonin transporter is found in hypertensive arteries.25 Patients with severe PAH have a relative deficiency of vasodilator pathways; they produce less endogenous prostacyclin, have reduced nitrogen oxide synthase (NOS) expression, and reduced vasoactive intestinal peptide (VIP) in the lungs.26,27

Prevention of pediatric pulmonary hypertension

Gene_expression (produce) of prostacyclin in fibroblast associated with pulmonary hypertension, hypertension, increased venous pressure under development and serotonin
19) Confidence 0.02 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.98 Pain Relevance 0.13
Prostacyclin (PGI2) – a metabolite of arachidonic acid – is endogenously produced by PGI2 synthase and released from pulmonary endothelial cells.
Gene_expression (produced) of Prostacyclin in endothelial cells
20) Confidence 0.01 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686263 Disease Relevance 0.97 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox